News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dimension Therapeutics (DMTX) Reports Second Quarter 2017 Financial Results And Provides Corporate Update



8/8/2017 12:44:08 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today reported financial results for the second quarter ended June 30, 2017, and provided a corporate update.

“Following our recently completed strategic review, we are focused on delivering key clinical milestones later this year and early in 2018 for multiple programs that have the potential to benefit people living with devastating rare and metabolic diseases associated with the liver,” said Annalisa Jenkins, MBBS, FRCP, Chief Executive Officer of Dimension. “We remain excited about our broad and unique IMD portfolio based on the AAV8 platform, and look forward to initial data later this year with DTX301 in OTC deficiency.”

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES